1084893-02-6

Basic information

• Product Name: N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)hydrazinecarbothioamide
• Synonyms: N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)hydrazinecarbothioamide
• CAS NO: 1084893-02-6
• Molecular Weight: 410.376
• Mol File: 1084893-02-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)hydrazinecarbothioamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)hydrazinecarbothioamide(1084893-02-6)
• EPA Substance Registry System: N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)hydrazinecarbothioamide(1084893-02-6)

Safety Data

• Hazardous Substances Data: 1084893-02-6(Hazardous Substances Data)

Upstream product

• 40207-03-2 p-Anisidinothioformyl-hydrazin 
• 169037-23-4 5-trifluoromethoxy-1H-indole-2,3-dione 
• 2284-20-0 4-Methoxyphenyl isothiocyanate 

Downstream Products

• 1084893-38-8 5-trifluoromethoxy-1-(morpholin-4-ylmethyl)-1H-indole-2,3-dione 3-[N-(4-methoxyphenyl)thiosemicarbazone] 

Relevant articles and documents

Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance

There is a constant need for new therapies against multidrug resistant (MDR) cancer. An attractive strategy is to develop chelators that display significant antitumor activity in multidrug resistant cancer cell lines overexpressing the drug efflux pump P-glycoprotein. In this study we used a panel of sensitive and MDR cancer cell lines to evaluate the toxicity of picolinylidene and salicylidene thiosemicarbazone, arylhydrazone, as well as picolinylidene and salicylidene hydrazino-benzothiazole derivatives. Our results confirm the collateral sensitivity of MDR cells to isatin-β-thiosemicarbazones, and identify several chelator scaffolds with a potential to overcome multidrug resistance. Analysis of structure-activity-relationships within the investigated compound library indicates that NNS and NNN donor chelators show superior toxicity as compared to ONS derivatives regardless of the resistance status of the cells.

Synthesis and antituberculosis activity of 5-methyl/trifluoromethoxy-1H-indole-2,3-dione 3-thiosemicarbazone derivatives

New series of 5-methyl/trifluoromethoxy-1H-indole-2,3-dione 3-thiosemicarbazones 3a-t, 1-methyl-5-methyl/trifluoromethoxy-1H-indole-2,3-dione 3-thiosemicarbazones 4a-y and 5-trifluoromethoxy-1-morpholinomethyl-1H-indole-2,3-dione 3-thiosemicarbazones 5a-m were synthesized. The structures of the synthesized compounds were confirmed by spectral data and elemental analysis. The new 5-methyl/trifluoromethoxy-1H-indole-2,3-dione derivatives, along with previously synthesized 5-methyl-1H-indole-2,3-dione 3-thiosemicarbazones 6a-l, were evaluated for in vitro antituberculosis activity against Mycobacterium tuberculosis H37Rv. 5-Methyl-1H-indole-2,3-dione 3-thiosemicarbazones (3b, 3d, 3f, 6c, 6d, and 6f), 5-trifluoromethoxy-1H-indole-2,3-dione 3-thiosemicarbazones (3q-s) and 5-trifluoromethoxy-1-morpholinomethyl-1H-indole-2,3-dione 3-thiosemicarbazones (5e and 5j-l) were found to be the most potent inhibitors of M. tuberculosis growth described in this study.